PharmTech Drug Digest 11.20
News|Articles|August 29, 2013

ATCC Announces Creation of Biomaterial Contributor Network

Author(s)Melanie Sena

ATCC creates Biomaterial Contributor Network to assist the research community.

ATCC

, a biological materials resource and standards organization, announces material deposit agreements with more than 30 public and private institutions. These institutions will have the option to participate in the biomaterial contributor network (BCN), and make research materials available to the research community. ATCC will coordinate with technology transfer offices at each institution to create a process for adding microbial strains and cell lines to the ATCC collection. Participants will have an opportunity to receive a share of the revenue from the sale and licensing of materials developed at their institutions. Over 225 biological materials are deposited under these agreements to date, with most available to both contributors and others as determined jointly by ATCC and the institution.

Source:

ATCC



Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.